10-Q: Harrow Inc. Reports Q3 2024 Results: Revenue Growth Offset by Net Loss
Quarterly Report
Harrow Inc. experienced a significant increase in product sales during the third quarter of 2024, but still reported a net loss due to increased operating expenses and interest costs.
Summary
- Harrow Inc. reported a net loss of $4.22 million for the third quarter of 2024, compared to a net loss of $4.39 million in the same period last year.
- Product sales increased significantly to $49.02 million in Q3 2024 from $31.81 million in Q3 2023, while other revenues decreased to $238,000 from $2.46 million.
- Total revenues for the quarter were $49.26 million, up from $34.27 million in the prior year.
- The company's operating expenses rose to $35.92 million in Q3 2024 from $22.45 million in Q3 2023.
- Interest expenses remained high at $5.53 million for the quarter.
- For the nine months ended September 30, 2024, Harrow reported a net loss of $24.26 million, compared to a net loss of $15.26 million for the same period in 2023.
- Product sales for the nine-month period were $132.40 million, up from $81.80 million in the prior year, while other revenues decreased to $385,000 from $12.03 million.
- Total revenues for the nine-month period were $132.78 million, up from $93.84 million in the prior year.
- The company's operating expenses for the nine-month period were $101.75 million, up from $60.19 million in the prior year.
- The company sold its investment in Eton Pharmaceuticals for net proceeds of $5.51 million, recording a loss of $3.17 million on the sale.
- The company drew down $30 million under its Oaktree Loan facility to partially fund a milestone payment to Novartis.
Sentiment
Score: 5
Explanation: The document presents mixed signals. While there is strong revenue growth, the continued net losses and high operating expenses are concerning. The cybersecurity incident and reliance on a single customer add to the negative sentiment. The company's strategic moves, such as the TRIESENCE re-launch and VEVYE launch, are positive, but the overall financial picture is still challenging.
Positives
- Product sales showed strong growth in both the third quarter and the nine-month period.
- The company successfully re-launched TRIESENCE following manufacturing qualifications.
- The company secured a Canadian out-license agreement with Apotex for several products.
- The company received clarification from CMS regarding IHEEZO reimbursement and increased the Medically Unlikely Edits (MUE) for IHEEZO's J-Code.
- The company launched VEVYE in the U.S. market.
Negatives
- The company continues to experience net losses, both for the quarter and the nine-month period.
- Other revenues decreased significantly in both the third quarter and the nine-month period.
- Operating expenses increased substantially, impacting profitability.
- Interest expenses remain high, contributing to the net loss.
- The company recorded a loss of $3.17 million on the sale of its investment in Eton Pharmaceuticals.
Risks
- The company is subject to regulatory standards and inspections that could impact its ability to sell certain products.
- The company relies on a single customer for a significant portion of its revenue.
- The company relies on three main suppliers for its active pharmaceutical ingredients.
- The company experienced a cybersecurity incident involving unauthorized access to an employee's email account.
- The company has a significant amount of debt, which could impact its financial flexibility.
Future Outlook
The company expects to use its current cash position, funds from operations, and any financing to pursue its business plan, including developing and commercializing drug candidates, integrating operations, and pursuing strategic transactions.
Industry Context
The company operates in the competitive eyecare pharmaceutical market, facing challenges from both branded and generic drug manufacturers, as well as compounding pharmacies. The company's focus on innovative ophthalmic products and its compounding business positions it to capitalize on market trends and patient needs.
Comparison to Industry Standards
- Harrow's revenue growth in product sales is a positive sign, but its continued net losses are a concern compared to industry leaders that have achieved profitability.
- The company's operating expenses are high, which is not uncommon for companies in the pharmaceutical industry, but it needs to manage these expenses to improve profitability.
- The company's debt levels are significant, which is a common challenge for companies in the pharmaceutical industry, but it needs to manage its debt to ensure financial stability.
- The company's reliance on a single customer for a significant portion of its revenue is a risk that needs to be addressed.
- The company's reliance on three main suppliers for its active pharmaceutical ingredients is a risk that needs to be addressed.
Legal Proceedings
- ImprimisRx, LLC has an ongoing lawsuit against Ocular Science, Inc. and OSRX, Inc. for copyright infringement, trademark infringement, unfair competition and false advertising.
Related Party Transactions
- The company has an investment in Melt Pharmaceuticals, Inc., and the company's CEO is a member of Melt's board of directors.
Stakeholder Impact
- Shareholders may be concerned about the continued net losses and the impact of the cybersecurity incident.
- Employees may be affected by any cost-cutting measures taken to address the financial challenges.
- Customers may benefit from the company's new product launches and expanded portfolio.
- Suppliers may be impacted by the company's efforts to manage costs and optimize its supply chain.
- Creditors may be concerned about the company's debt levels and its ability to meet its financial obligations.
Next Steps
- The company will continue to work diligently to fully investigate and assess the impact of the cybersecurity incident.
- The company will focus on increasing revenues of its branded pharmaceutical products and proprietary compounded formulations.
- The company will continue to pursue development and commercialization opportunities for its ophthalmology assets.
- The company will work to optimize pricing and obtain reimbursement options for its drug products.
Key Dates
| Date | Description |
|---|---|
| 2019-02-01 | Start date of Management Services Agreement with Melt Pharmaceuticals, Inc. |
| 2020-07-01 | Effective date of lease amendment for Ledgewood facility. |
| 2021-04-01 | Date of offering of 8.625% Senior Notes due 2026. |
| 2021-05-01 | Date of lease amendment for Ledgewood facility. |
| 2022-01-01 | Commencement of operating lease for Carlsbad office space. |
| 2022-09-01 | Commencement of operating lease for Nashville lab and office space. |
| 2022-12-01 | Date of offering of 11.875% Senior Notes due 2027. |
| 2023-03-01 | Date of Oaktree Loan Credit Agreement. |
| 2023-07-01 | Termination date of Management Services Agreement with Melt Pharmaceuticals, Inc. |
| 2024-01-01 | Launch of VEVYE in the U.S. market. |
| 2024-03-01 | Date of operating lease for new Nashville corporate headquarters. |
| 2024-03-27 | Date of reduction of Tranche B commitment under Oaktree Loan. |
| 2024-07-01 | Effective date of increased MUE for IHEEZO's J-Code. |
| 2024-10-25 | Date of Second Amendment to Credit Agreement and Guaranty with Oaktree. |
| 2024-11-12 | Date of outstanding shares of common stock. |
Keywords
pharmaceuticals, ophthalmic, product sales, net loss, EBITDA, revenue, ImprimisRx, branded products, debt, Oaktree Loan, TRIESENCE, VEVYE, IHEEZO, cybersecurity
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.